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Background: Circulating tumor cell (CTCs) counts might serve as early surrogate marker for treatment efficacy in
metastatic castration-resistant prostate cancer (mCRPC) patients. We prospectively assessed categorical and continuous
CTC-counts for their utility in early prediction of radiographic response, progression-free (PFS) and overall survival (OS)
in mCRPC patients treated with docetaxel.
Methods: CTC-counts were assessed in 122 serial samples, as continuous or categorical (<5 vs. ≥5 CTCs) variables, at
baseline (q0) and after 1 (q1), 4 (q4) and 10 (q10) cycles of docetaxel (3-weekly, 75 mg/m2) in 33 mCRPC patients.
Treatment response (TR) was defined as non-progressive (non-PD) and progressive disease (PD), by morphologic
RECIST or clinical criteria at q4 and q10. Binary logistic and Cox proportional hazards regression analyses were used
as statistical methods.
Results: Categorical CTC-count status predicted PD at q4 already after one cycle (q1) and after 4 cycles (q4) of
chemotherapy with an odds ratio (OR) of 14.9 (p = 0.02) and 18.0 (p = 0.01). Continuous CTC-values predicted PD
only at q4 (OR 1.04, p = 0.048). Regarding PFS, categorical CTC-counts at q1 were independent prognostic markers
with a hazard ratio (HR) of 3.85 (95 % CI 1.1-13.8, p = 0.04) whereas early continuous CTC-values at q1 failed significance
(HR 1.02, 95 % CI 0.99-1.05, p = 0.14). For OS early categorical and continuous CTC-counts were independent prognostic
markers at q1 with a HR of 3.0 (95 % CI 1.6-15.7, p = 0.007) and 1.02 (95 % CI 1.0-1.040, p = 0.04).
Conclusions: Categorical CTC-count status is an early independent predictor for TR, PFS and OS only 3 weeks following
treatment initiation with docetaxel whereas continuous CTC-counts were an inconsistent surrogate marker in mCRPC
patients. For clinical practice, categorical CTC-counts may provide complementary information towards individualized
treatment strategies with early prediction of treatment efficacy and optimized sequential treatment.
Keywords: Biomarkers, Circulating tumor cells, CTCs, Personalized treatment, Prostate cancer, Treatment efficacy* Correspondence: mark.thalgott@lrz.tum.de
†Equal contributors
1Department of Urology, Klinikum rechts der Isar, Technische Universität
München, Ismaningerstraße 22, 81675 Munich, Germany
Full list of author information is available at the end of the article
© 2015 Thalgott et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Thalgott et al. BMC Cancer  (2015) 15:458 Page 2 of 10Background
In patients with metastatic castration resistant prostate
cancer (mCRPC) first-line cytotoxic therapy with doce-
taxel is standard of care. About 45 % of patients are pri-
mary non-responders and tumor progression occurs
after a median of 6–8 months [1–4]. Thus, early predic-
tion of treatment efficacy is relevant for optimized and
individualized treatment strategies, especially since re-
cently newer agents like abiraterone, enzalutamide and
radium-223 were established which may enable sequen-
tial treatment strategies and are applicable either prior
or secondary to docetaxel [5–7].
During therapy, objective treatment response (TR) is
routinely monitored with computed tomography (CT)
and by additional bone scintigraphy with T-99 m labeled
diphosphonates every four to six cycles of chemotherapy.
Thus, the first response evaluation is performed 3–4
months after therapy initiation [6, 8]. Also, the prostate-
specific antigen (PSA) value as a tumor marker requires
a treatment interval of about 3 months to reach prog-
nostic significance and is unreliable to reveal treatment
response, as is the case with other serum derived
markers such as lactate dehydrogenase and alkaline
phosphatase [5, 9–12].
Consequently, there is a demand for a reliable predict-
ive surrogate marker as an early indicator of treatment
efficacy. A potential blood derived biomarker is the
quantitative detection of circulating tumor cells (CTCs)
that are highly investigated [13–18]. A US federal Food
and Drug Administration (FDA) approved device for
CTC-quantification and treatment monitoring in meta-
static PC is the CellSearch™-System. Using this device, a
threshold of ≥5 CTCs per 7.5 ml blood demonstrated
prognostic significance for overall survival (OS) in meta-
static PC [9–11].
There is evidence that CTC-counts are an early pre-
dictive surrogate marker for objective TR in breast and
colorectal cancer [19–22]. Similarly in mCRPC patients
elevated pre-treatment CTC-counts are associated with
reduced radiologic response rates [23]. Therefore, we
performed a prospective study in mCRPC patients,
assessing longitudinal categorical and continuous CTC-
count status during therapy in association with response
assessments by radiographic RECIST- (Response Evaluation
Criteria In Solid Tumors) and clinical criteria. The main
objective was to compare the predictive and prognostic
value of early categorical and continuous CTC-count
status, after one cycle of chemotherapy for objective
therapy response (TR), progression free (PFS) and overall
survival (OS).
Methods
This prospective clinical validation study was approved
by the ethics committee of the Klinikum rechts der Isar,Technische Universität München, Germany and was
performed according to the ethical standards of the Dec-
laration of Helsinki. All patients gave written informed
consent. In total, 33 consecutive mCRPC patients under-
going first line docetaxel therapy (3-weekly, 75 mg/m2)
were accrued from June 2008 to July 2010 at the Depart-
ment of Urology, Technische Universität München,
Germany. The main exclusion criterion was a second
malignancy. Response monitoring was conducted by
radiographic RECIST (rTR) and clinical criteria (cTR)
after the fourth (q4) and tenth cycle (q10) of docetaxel
and finally after two months of drug holiday (FU). CTCs
were collected at baseline (q0) and after the first (q1),
fourth (q4) and tenth (q10) cycle (Fig. 1). The main
objective was to assess the predictive and prognostic
value of early continuous and categorical CTC-counts
for treatment response as well as progression free (PFS)
and overall survival (OS).
Blood analysis
Enumeration of CTCs was performed as described earlier
using the CellSearch™-System (Veridex, Raritan, NJ, USA)
according to the manufacturer’s protocol [9–11, 24, 25]. In
brief, 7.5 ml blood was collected into CellSave™Preserva-
tive Tubes and processed within 96 h. Cells were isolated
using the automated CellTracks®AutoPrep-System and
CellSearch™Epithelial Cell Reagent Kit and identified with
the CellSpotter™Analyzer. CTCs were characterized by
EpCAM (epithelial cancer adhesion molecule) and staining
for cytokeratin and nucleic acid as epithelial markers.
CTCs were verified in a blinded fashion independently
by two trained operators at the University of Munich,
Germany. Routine laboratory analyses were performed at
the clinical site, including PSA, lactate dehydrogenase,
alkaline phosphatase and hemoglobin.
Response evaluation
Response assessments were performed independently,
with assessors blinded to CTC-results. A board certified
radiologist evaluated the CT-scans according to RECIST
1.1 criteria for rTR, dichotomized into progressive dis-
ease (PD) or non-progressive disease (non-PD) [26]. Sin-
gular CT-scans were performed without intravenous
contrast agent, e.g. due to renal insufficiency. In these
cases RECIST criteria were used when the selected target
lesions were measurable. If not, PD was defined by ap-
pearance of new metastases. For cTR, a genitourinary
oncology physician subsumed the results of CT-scans
and concomitant bone scans. Progression on bone scans
was indicated by ≥2 new lesions [26, 27]. Additionally
medical assessments including symptomatic progression
and performance status as well as routine laboratory
results like AP, LDH and PSA-values were taken into
account with increasing levels indicating progression,
Fig. 1 Study design
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sessments treatment was aborted preterm in case of PD.
Statistical Analysis
Sample sizes were calculated with a precision of ±20 %
for an exact two-sided 95 % confidence interval for a
proportion of 25 patients with detectable CTCs at base-
line, amenable for response evaluation. The longitudinal
course of CTC-counts as a continuous variable was ana-
lyzed as a function of the TR (PD vs. non-PD). Continu-
ous CTC-counts were defined as absolute CTC-values in
patients with PD and non-PD. Differences among groups
and changes over time were compared using median
CTC-count values. Differences were compared using the
Mann–Whitney-Test and the predictive value for PD
was assessed by binary logistic regressions. Secondary
CTC-counts were handled as a categorical variable. Cat-
egorical CTC-counts were dichotomized according to
the established threshold of <5 vs. ≥5 CTCs analogous
to prognostic favorable and unfavorable CTC-counts de-
scribed in the current literature and according to the
FDA approved procedure [10]. Using this threshold, bin-
ary logistic regressions determined the predictive power
for PD. Estimates of PFS and OS were analyzed using
the Kaplan-Meier method, and differences thereof with
the log-rank test. Cox proportional hazards regression
analyses were used to determine the prognostic value of
CTC-counts for PFS and OS. PFS was defined as the
interval between baseline CTC-draw and the finding of a
PD by rTR assessments or death and OS as the elapsed
time from baseline CTC-collection to death or the last
follow-up. PFS-time was limited by the defined FU-
assessment. Tests were two-sided and were analyzed ex-
ploratory with α = 5 % using SPSS version 21 (SPSS Inc.,
Chicago, IL, USA).
Results
Patient demographics and response evaluation
The clinical characteristics of enrolled mCRPC patients
are summarized in Table 1. Patients received a total of235 cycles docetaxel with a median of 10 (3–10). Land-
mark analyses for CTC-counts were performed in a total
of 122 samples. Concomitant objective rTR and cTR as-
sessments were realized in 33 patients at q4, in 23 at q10
and 18 patients at FU. CTCs were detected in 27/33
(81.8 %, 95 % CI (64.5, 93.0)) of patients at baseline, in 24/
33 (72.7 %, 95 % CI (54.5, 86.7)) at q1, in 20/33 (60.6 %,
95 % CI (42.1, 77.1)) at q4 and finally 14/23 (60.1 %, 95 %
CI (38.5, 80.3)) at q10. Median intervals from CTC-
collection at q0, q1 and q4 to rTR at q4 were 2.9 (2.4-4.7),
2.1 (1.7-3.66) and 0.0 months (0.0-0.4) while the interval
from baseline to q10 or end of treatment was 7.2 months
(4.0-9.0) and to FU 8.9 months (5.0-10.9). At the time of
data analysis, 72.7 % (n = 24) of patients had died, resulting
in a median OS of 10.7 months (95 % CI 5.8-15.6) and
median PFS was 8.5 months (95 % CI 6.6-10.5).
Predictive power of categorical and continuous CTC-counts
for therapy response
We further investigated the predictive power of early
categorical CTC-counts (<5 vs. ≥5 CTCs) in logistic re-
gression analyses (Table 2). Baseline CTC-values (q0)
did not display predictive significance. In contrast, early
unfavorable post-treatment CTC-counts at q1 were sig-
nificantly predictive for PD at q4 with an odds ratio of
14.9 (p = 0.02) for rTR and 19.4 (p = 0.01) for cTR. In
concomitant CTC-analyses at q4 and q10, the threshold
of ≥5 CTCs was predictive for rTR, whereas for cTR
only CTC-counts at q4 provided a predictive value (Table 2).
Thus, early, categorical post-treatment CTC-counts <5
vs. ≥5 CTCs presented a powerful early indicator of
treatment response with a median of 2.1 (1.7-3.7) months
before the first routine response evaluation.
Comparing early median values of continuous CTC-
counts from patients with non-PD vs. PD at q4, as the
earliest time point of TR evaluation, significant higher
median CTC-counts were found in patients with PD at
q0, q1 and q4 (Table 3). Focusing on the course of early
continuous CTC-counts, we individually assessed CTC-
kinetics in patients with PD or non-PD from q0 to q1
Table 1 Clinical and pathological characteristics of the study cohort








Gleason score at diagnosis, n (%)
Unknown 3 (9.1)
≤ 7 11 (33.3)
≥ 8 19 (57.6)




Metastatic sites, n (%)
Soft tissue 3 (9.0)
Bone + LN 15 (45.5)




Lactate dehydrogenase [U/l] 320
218-1900




ECOG, eastern cooperative oncology group; EBRT, external beam radiotherapy;
LN, lymph node metastases; PSA, prostate-specific antigen; RP, radical
prostatectomy; n, number
avalues given as median and range
Table 2 Predictive power of continuous and categorical CTC-counts
R
CTC-assessment Interval Patients (n=) O
Continuous CTC-values CTC q0 with OR at q4 33 1.
CTC q1 with OR at q4 33 1.
CTC q4 with OR at q4 33 1.
CTC q10 with OR at q10 23 1.
Categorical CTC-counts CTC q0 with OR at q4 33 6.
CTC q1 with OR at q4 33 14
CTC q4 with OR at q4 33 18
CTC q10 with OR at q10 23 16
q, cycle of docetaxel; OR, objective response
p values indicate statistical significance
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CTC-decrease was found from q0 to q1. However, dur-
ing the further course from q1 to q4, the CTC kinetic
remained stable in patients with non-PD, whereas pa-
tients with PD displayed an increase in median CTC-
counts (Table 3). Consequently early continuous CTC
count status at q0 and q1 revealed no predictive value
for PD at q4 in logistic regression analyses. In contrast,
CTC-counts at q4 were significantly associated with PD
assessed by concomitant rTR (p = 0.048) and cTR (p =
0.009). Interestingly, CTC-counts at q10 displayed no
predictive significance (Table 2). Thus the continuous
CTC-count status predicts treatment efficacy only when
a therapy interval of about 12 weeks is reached.
Prognostic value of categorical and continuous CTC-counts
for progression free survival
According to the main objective of the study we focused
on the prognostic value of early categorical CTC-counts
(<5 vs. ≥5 CTCs) and early continuous CTC-counts in
correlation with PFS and OS. PFS was analyzed accord-
ing to morphologic RECIST criteria due to almost equal
results for rTR and cTR in the association analyses.
According to categorical CTC-counts, Kaplan Meier
analyses revealed significant differences for PFS at each
time point after treatment initiation when comparing
patients with favorable (<5 CTCs) vs. unfavorable CTC-
counts (≥5 CTCs) with a median of 10.9 (95 % CI 5.6-
16.3) vs. 4.1 (95 % CI 1.5-6.7) months at q1 (p = 0.002)
and 10.9 (95 % CI 5.5-16.3) vs. 4.7 (95 % CI 3.2-6.2)
months at q4 (p = 0.01), respectively. Baseline CTC-
counts were not prognostic for PFS (p = 0.09) (median
PFS for patients with <5 CTCs not reached vs.
5.0 months (95 % CI 1.7-8.3) in patients with ≥5 CTCs)
(Fig. 2). Consequently, for categorical post-treatment
CTC-results at q1 and q4 the Cox proportional hazard
ratio for PD was individually highly prognostic for PFS
with 4.3 (95 % CI 1.6-11.8) and 3.2 (95 % CI 1.2-8.6).
Similarly early continuous post-treatment CTC-counts atfor therapy response
adiographic evaluation Clinical criteria
dds Ratio 95 % CI p= Odds Ratio 95 % CI p=
0 0.99-1.02 0.53 1.0 0.99-1.04 0.17
03 0.99-1.07 0.17 1.1 0.99-1.13 0.06
04 1.0-1.09 0.048 1.1 1.03-1.26 0.009
02 0.98-1.07 0.28 1.1 1.0-1.23 0.052
5 0.7-60.5 0.1 8.0 0.86-74.2 0.07
.9 1.6-142.2 0.02 19.4 2.0-185.7 0.01
.0 1.9-174.2 0.01 24.0 2.5-233.5 0.006
.3 1.4-183.1 0.02 5.0 0.82-30.5 0.08
Table 3 Variance of continuous CTC-counts according to therapy response after four (q4) or ten cycles (q10) of docetaxel
Response CTC-Detection Radiographic evaluation Clinical criteria
q0a q1a q4 q10 q0a q1a q4 q10
non-PD Median, Range 5 1 0 0 4.5 1 0 0
0-225 0-85 0-115 0-73 0-97 0-38 0-29 0-71
Patients, n= 25 25 25 17 24 24 24 14
PD Median, Range 24 9.5 32 23 22 11 34 17
4-97 1-58 3-358 0-36 4-225 1-85 3-358 0-73
Patients, n= 8 8 8 6 9 9 9 9
Significance, p= 0.04 0.01 <0.001 0.03 0.03 0.004 <0.001 0.03
PD, progressive disease according to therapy response assessment at q4 or q10; q, cycle of docetaxel
aCTC-variance was assessed as a function of objective response at q4
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PFS, but with a distinct lower hazard ratio of 1.02 (95 %
CI 1.0-1.05) and 1.01 (95%CI 1.0-1.02) when compared to
the values obtained for categorical CTC-counts. Baseline
CTC-status was not predictive for PFS, neither by cat-
egorical nor by continuous CTC-assessments (Table 4).
Prognostic value of categorical and continuous CTC-counts
for overall survival
Regarding OS, categorical CTC-counts (<5 vs. ≥5 CTCs)
significantly distinguished between favorable und unfavor-
able OS at each time point of CTC-sampling including
baseline with a median OS of 24.8 (95% CI not defined) vs.
9.0 (95 % CI 7.7-10.4) months (q0; p = 0.005), and post-
treatment values with a median OS of 22.4 (95 % CI 20.2-
24.6) vs. 8.5 (95 % CI 6.6-10.5) months at q1 (p = 0.001)
and a median OS of 24.6 (95 % CI 16.9-32.3) vs. 8.5 (95 %Fig. 2 Kaplan Meier analyses for progression free survival (PFS)
according to categorical CTC-counts (<5 vs. ≥5) at baseline (q0) and
after one (q1) and 4 (q4) cycles of docetaxelCI 7.5-9.6) months at q4 (p = 0.001) (Fig. 3). Consequently,
Cox proportional hazard regression analyses revealed cat-
egorical CTC-counts highly prognostic for OS with a HR of
3.8 (95 % CI 1.4-10.3) at baseline and a HR of 4.5 (95 % CI
1.9-10.8) at q1 and 5.8 (95 % CI 2.2-15.1) at q4.
In contrast continuous baseline CTC-values failed sig-
nificance (HR 1.01, 95 % CI 0.99-1.01, p = 0.07) whereas
early continuous post-treatment CTC-counts at q1 and
q4 revealed prognostic significance for OS with a low
HR of 1.02 (95 % CI 1.01-1.04) and 1.02 (95 % CI 1.01-
1.03), respectively (Table 4).
Multivariate regression analyses
On multivariate Cox proportional hazards regression
analyses analysis we compared categorical and continuous
CTC-counts at the earliest time point of CTC-sampling
after treatment initiation (q1) with concomitant routine
laboratory analyses and a PSA-decline of ≥30 % (Table 5).
Categorical CTC-counts at q1 were confirmed as inde-
pendent predictors for PFS with a HR of 3.9 (95 % CI
1.1-13.8, p = 0.04). In contrast continuous CTC-values
displayed no independent prognostic value for PFS with a
HR of 1.02 (95 % CI 0.99-1.05, p = 0.14). Concerning cox
regression analysis for OS, both categorical CTC-counts
and continuous CTC-counts revealed an independent sig-
nificant prognostic value for OS with a HR of 4.9 (95 % CI
1.6-15.7, p = 0.007) and 1.02 (95 % CI 1.0-1.04, p = 0.04),
respectively.
Exploratory analyses for the prognostic value of
CTC-dynamics
As presented in Additional files 1, 2, 3 and 4 we per-
formed further exploratory analyses investigating early
CTC-dynamics from q0 to q1. We could demonstrate
the conversion of CTC-counts below the established
threshold of 5 CTCs relevant for PFS and OS. Similarly,
a 50 % decrease algorithm as a potential measure of con-
tinuous CTC-value changes revealed prognostic impact
on OS and PFS. Assessing the 50 % decrease, 44 % of
the patients reaching the 50 % decline in CTC-counts
Table 4 Cox proportional hazards regression analyses for progression free (PFS) and overall survival (OS) as a function of continuous
and categorical (<5 CTCs vs. ≥5 CTCs) CTC-counts
PFS OS
CTC-assessment Interval Patients (n=) Hazard ratio 95 % CI p= Hazard ratio 95 % CI p=
Continuous CTC-values q0 33 1.01 0.99-1.02 0.4 1.01 0.999-1.01 0.07
q1 33 1.02 1.0-1.05 0.04 1.02 1.01-1.04 0.01
q4 33 1.01 1.0-1.02 0.004 1.02 1.01-1.03 0.001
q10 23 1.02 0.99-1.04 0.3 1.03 1.01-1.05 0.004
Categorical CTC-counts q0 33 2.4 0.9-6.8 0.1 3.8 1.4-10.3 0.009
q1 33 4.3 1.6-11.8 0.005 4.5 1.9-10.8 0.001
q4 33 3.2 1.2-8.6 0.02 5.8 2.2-15.1 <0.001
q10 23 6.7 1.3-33.7 0.02 5.6 1.7-18.4 0.004
p values indicate statistical significance
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the threshold of 5 CTCs.
Discussion
In this prospective clinical trial we examined the predictive
and prognostic value of early CTC-count status for moni-
toring treatment efficacy in mCRPC patients. To the best
of our knowledge this is the first study that comparatively
investigates the predictive and prognostic value of early
continuous vs. categorical CTC-count status for therapy
response in a homogenous cohort of mCRPC patients,
assessing several defined longitudinal time points during
chemotherapy with docetaxel. According to our data, cat-
egorical CTC-count status relative to a threshold of 5
CTCs is an early predictor of treatment response, alreadyFig. 3 Kaplan Meier analyses for overall survival (OS) according to
categorical CTC-counts (<5 vs. ≥5) at baseline (q0) and after one
(q1) and 4 (q4) cycles of docetaxelat the end of the first cycle of chemotherapy, 9–12 weeks
before the first radiologic objective response assessment.
In contrast early continuous CTC-values displayed no
early predictive value for therapy response by morphologic
RECIST or clinical criteria. The predictive value of early
categorical post-treatment CTC-count status for therapy
response was similarly observed in metastatic breast and
colorectal cancer [19–21, 30]. In our cohort pretreatment
CTC-counts were not associated with therapy response. In
contrast earlier results in mCRPC-patients revealed an as-
sociation of elevated baseline CTC-counts (≥5 CTCs) with
reduced radiologic and biochemical response while the
post-treatment CTC-dynamic revealed an association with
PSA-response [23].
Focusing on the predictive value of the continuous
CTC-count status for therapy response, early continuous
CTC-values at q1 were not predictive for objective re-
sponse, although the comparison of median absolute
CTC-counts significantly differed in patients with PD vs.
non-PD at all time points. The missing predictive value
of continuous CTC-counts might be reflected by the
CTC-kinetics. After one cycle of chemotherapy early
CTC-kinetics revealed a decrease of median CTC-values
in non-PD and PD patients alike. According to rTR in
non-PD patients the initial median CTC decrease was
80 % (p = 0.002) and in PD patients 60.4 % (p = 0.1) and
for cTR 77.7 % (p = 0.002) and 50 % (p = 0.086). How-
ever, at later stages during therapy an increase of median
CTC-counts was measured only in patients with PD.
Therefore, continuous CTC-counts seem to require an
interval of up to 12 weeks to reflect therapy response in
imaging devices. To our knowledge we are the first to
present analyses of continuous CTC-count status in rela-
tion to radiologic response, during a defined course of
docetaxel in mCRPC patients. Earlier studies investi-
gated the association and predictive value of directional
or delta changes of log10 transformed CTCs with
clinical response in overall interval-adjusted analyses
Table 5 Multivariate Cox proportional hazards regression for progression free (PFS) and overall survival (OS) in a model including
post-treatment laboratory analyses after one cycle of docetaxel (q1) with either continuous or categorical CTC-counts
PFS OS
CTC-assessment Values in model Hazard ratio 95 % CI p= Hazard ratio 95 % CI p=
Continuous CTC-values CTC-value Continuous 1.02 0.99-1.05 0.14 1.02 1.01-1.04 0.04
PSA-value ≥30 % decline 1.8 0.6-5.6 0.3 2.6 0.9-7.78 0.09
Lactate dehydrogenase ≤ ULN vs. >ULN 1.2 0.2-10.2 0.8 0.7 0.1-3.4 0.65
Alkaline phosphatase ≤ ULN vs. >ULN 3.2 0.95-10.99 0.06 3.4 1.1-10.3 0.03
Hemoglobin < LLN vs. ≥LLN 2.7 0.3-28.4 0.4 1.7 0.2-17.0 0.63
Categorical CTC-counts CTC-count <5 CTCs vs. ≥5 CTCs 3.9 1.1-13.8 0.04 4.9 1.6-15.7 0.007
PSA-value ≥30 % decline 1.8 0.6-5.3 0.3 3.0 1.03-8.8 0.04
Lactate ehydrogenase ≤ ULN vs. >ULN 1.5 0.2-11.8 0.7 0.8 0.2-3.9 0.84
Alkaline phosphatase ≤ ULN vs. >ULN 1.9 0.5-7.4 0.4 2.0 0.6-6.5 0.27
Hemoglobin < LLN vs. ≥LLN 3.3 0.3-34.3 0.3 2.2 0.2-21.0 0.5
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were not predictive for clinical PD, neither by unidirec-
tional nor by delta changes despite a trend for increasing
CTC-counts in patients with PD and relatively un-
changed values in non-PD. In this cohort mean changes
in CTC-counts did not differ significantly between pa-
tients with PD vs. non-PD [28]. In contrast, investigating
a mixed cohort of castration sensitive (CSPC) and
mCRPC patients, an average CTC-decrease in non-PD
and a CTC-increase in PD patients was observed, with a
significant individual predictive value of CTC-value
changes for the risk of clinical progression. Concordance
analyses of directional CTC-changes with clinical out-
come revealed a sensitivity of 79 % and a specificity of
75 % [29]. Similarly Goodman et al. demonstrated in
analyses conducted on log10 transformation of CTC-
counts that elevated CTC numbers during treatment were
associated with a higher risk for transition from HSPC to
CRPC. In this study only baseline CTC-counts were
independently prognostic for the risk of CRPC [31].
Thus, there is an inconsistent body of evidence con-
cerning whether continuous CTC-counts might have
predictive value for therapy response. Our results indi-
cate that continuous CTC-counts as a predictive marker
require sampling at multiple time points over a period
of up to 12 weeks. This is in accordance with a larger
study that included different types of cancers, and which
demonstrated that about 3 months are needed to moni-
tor the treatment effect on continuously assessed CTCs
[32]. Comparing different concepts of % change in CTCs
with a defined % reduction confidence or fold changes
with absolute and proportional reduction cutoffs vs. cat-
egorical CTC-enumeration demonstrated that a static
CTC cutoff is the best method to determine whether a
therapy is effective [32]. Similarly a fold change in CTC-
counts was only moderately associated with survivaltime and proportional changes of continuous CTC-
counts with ≥30 % or ≥50 % revealed conflictive results
with respect to survival [11, 23, 27].
Focusing on PFS we could demonstrate that early
categorical posttreatment CTC-counts were highly prog-
nostic, as was demonstrated earlier for other carcinomas
[19, 20, 30, 33]. In addition, we demonstrated categorical
CTC-counts, after the first cycle of docetaxel, as an
independent prognostic marker for PFS. Interestingly, in
our study baseline CTC-values did not display prognos-
tic value for PFS. This contrasts earlier results in CSPC
patients, where unfavorable categorical baseline and
posttreatment CTC-counts were associated with reduced
time to castration-refractory stages, but is in accordance
with results in metastatic colorectal cancer [20, 31, 34].
Investigating the continuous CTC-count status as a
prognostic tool for PFS, in our study post-treatment
CTC-values displayed a significant prognostic value,
despite a distinct lower hazard ratio when compared to
categorical CTC-counts. Consequently early continuous
CTC-counts after one cycle of docetaxel were not inde-
pendently prognostic for PFS. Therefore early categorical
posttreatment CTC-counts seem to be a superior prog-
nostic marker for PFS, when compared to the continu-
ous CTC-value status.
In our study response was primary defined by the ob-
jective radiologic response (rTR) performed by RECIST
1.1 criteria and secondary by clinical response (cTR).
Both modalities were rated blinded to CTC-assessments.
With regard to the selected RECIST 1.1 criteria, we han-
dled bone metastases as non-measurable lesions as all of
the bone metastases being present in the patients exam-
ined by our study show no measurable soft-tissue com-
ponent. Patients with non-measurable disease only at
baseline were allowed, with a defined PD in case of an
increased tumor burden or a substantial worsening as
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ance with earlier studies using RECIST criteria but might
be limited due to a potential misinterpretation of a
radiographic flare response with sclerosing of osseous
metastases as PD. It is well known that under various
therapies in bone metastases an increased activity of os-
teoblasts can occur resulting in an higher density in CT
which could be misinterpreted as progressive disease
[11, 31, 35]. However, it has to be taken into account
that the interpretation as PD defined by RECIST 1.1 re-
quires an uniequivocal progression with a total increase
in tumor burden. An only modest increase is not
regarded as enough for PD in non-target lesions. This
approach as conducted in our study limits, however not
completely omits the incorrect classification of patients
with stable disease as PD. In our trial the additionally
evaluated clinical response (cTR) revealed similar results
when compared to rTR. Similar to earlier studies cTR was
assessed mainly based on imaging findings with RECIST
evaluations of CT-scans and concomitant bone scans
where new lesions (≥2) indicated progression [26–28].
Supplementary, medical assessments including symptom-
atic progression and performance status were taken into
account, and to a lesser extent laboratory studies with in-
creasing PSA, LDH and AP levels indicating progression
[11, 28]. Beside the objective rTR evaluation by RECIST
criteria, the cTR assessment in our study may incorporate
a subjective bias and represents a limitation. Therefore
further studies should apply defined weight bearing
percentages for the individual clinical criteria as dem-
onstrated by Gonzales et al. or should consider the rec-
ommendations of the prostate cancer clinical trials
working group (PCWG2 guidelines) for response as-
sessment [26, 27, 29].
Focusing on OS, categorical CTC-count status dis-
played a significant association with OS for each time
point during therapy including baseline. Early categor-
ical CTC-counts at q1 were confirmed as an independ-
ent prognostic surrogate for OS. Thus, our data
complement other studies in which the prognostic
value of a defined CTC-threshold for OS has been
demonstrated for baseline and 2–5 weeks after therapy
induction or during later intervals [10, 11, 23, 34, 36].
Although the delineated threshold for survival varies
across studies from 3 to 5 CTCs [9–11, 24, 31, 34, 36–38]
in our study the FDA-approved threshold for therapy
monitoring of <5 vs. ≥5 CTCs was applicable as a pre-
dictor of treatment efficacy in our cohort. Regarding
continuous CTC-values our study revealed also the
early posttreatment continuous CTC status as an inde-
pendent prognostic marker for OS at q1 despite a lower
hazard ratio when compared to categorical CTC-counts.
These results supplement earlier data by Scher et al.
demonstrating that elevated continuous CTC-valueswere associated with a higher risk of death and de-
creased survival [27].
As presented in additional files (Additional files 1, 2, 3
and 4) we performed further exploratory analyses inves-
tigating early CTC-dynamics from q0 to q1. We could
demonstrate the conversion of CTC-counts below the
established threshold of 5 CTCs relevant for PFS and
OS, as was demonstrated earlier for OS [10, 11, 23].
Similarly, a 50 % decrease algorithm as a potential meas-
ure of continuous CTC-value changes revealed prognos-
tic impact on OS and PFS. Assessing the 50 % decrease,
44 % of the patients reaching the 50 % decline in CTC-
counts simultaneously demonstrated a CTC-count de-
crease below the threshold of 5 CTCs. Our results
complement initial trials demonstrating that not only
the conversion of CTC-counts to a favorable level of <5
CTCs, but also a percent decrease shows a prognostic
value for survival in mCRPC patients as it was demon-
strated initially for OS by using a proportional fall of ≥30 %
of continuously assessed CTC-counts [11]. In contrast a
recent study demonstrated no significant association of a
50 % decrease with OS [23]. Thus there is inconsistent
evidence regarding the prognostic value of continuous
CTC-values for survival whereas the prognostic value of
categorical CTC-counts was confirmed in a broad range
of trials with respect to OS. Taken together categorical
CTC-counts seem to be a superior surrogate marker
when compared to continuous CTC-values presenting
in our study a higher hazard ratio for survival and a clin-
ically easily applicable threshold with an early predictive
value for objective treatment response. In addition cat-
egorical CTC-counts displayed an early independent value
for PFS and OS, applicable already after one cycle of
chemotherapy, up to 3.7 months before the first imaging
staging procedures. Therefore, the aim of therapies should
be the conversion of CTC-counts to favorable values, as
has been suggested also by others [32]. Limiting our
results might be attributed to the small patient cohort and
need to be confirmed in a large cohort especially with
regard to randomized CTC-guided treatment strategies.
In addition further studies need to address the molecular
characterization of CTCs as a liquid biopsy [39–42].
Conclusions
Our data give evidence for early categorical CTC-count
enumeration, but not for continuous CTC-values, as a
predictive molecular surrogate marker for treatment re-
sponse in mCRPC patients up to 3.7 months before the
first radiographic evaluation. In addition our findings
suggest early categorical posttreatment CTC-count sta-
tus (<5 vs. ≥5 CTCs), already after one cycle of therapy,
as an independent prognostic marker for PFS and OS,
whereas continuous CTC-values displayed an inconsistent
prognostic value.
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Additional file 1: Kaplan Meier analyses for progression free survival
in dependency of early CTC-dynamics relative to the threshold of 5
CTCs (<5 vs. ≥5) for the interval from baseline (q0) to the end of the
first cycle docetaxel (q1).
Additional file 2: Kaplan Meier analyses for progression free survival
in dependency of early CTC-dynamics relative to a CTC-count decrease
of ≥50 % for the interval from baseline (q0) to the end of the first
cycle docetaxel (q1).
Additional file 3: Kaplan Meier analyses for overall survival (OS)
according to CTC-dynamics relative to a threshold of 5 CTCs (<5
vs. ≥5) for the interval from baseline (q0) to the end of the first
cycle docetaxel (q1).
Additional file 4: Kaplan Meier analyses for overall survival (OS)
according to CTC-dynamics relative to a CTC-count decrease of ≥50 %
for the interval from baseline (q0) to the end of the first cycle
docetaxel (q1).
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